

Provider Bulletin



News and Information

May 21, 2024

Updated Prior Authorization Criteria for Drugs on the UCare Individual & Family Plans and UCare Individual & Family Plans with M Health Fairview Plans Formulary

On July 1, 2024 prior authorization criteria for the drugs listed below will be updated. These changes will be reflected in the [2024 Prior Authorization Criteria](#) forms.

Drug or category	Criteria change
Xtandi (enzalutamide) 40 mg capsules and 40 and 80 mg tablets for non-metastatic castration-sensitive prostate cancer.	Prior authorization criteria for enzalutamide standardly includes the requirement that it is prescribed by, or in consultation with, an oncologist. This specialist requirement was unintentionally omitted when updating criteria for the new indication of non-metastatic castration-sensitive prostate cancer. The criteria will be updated appropriately to include the standard specialist requirement.

[Pharmacy resources](#) are available on the UCare Provider website.